Pharmaceutical companies and academic research centers have long struggled with expensive, time-consuming, single-agent clinical trials that frequently fail to unravel complex chronic ailments such as Fibromyalgia, ME/CFS, IBS, and now Long COVID. These traditional approaches have fallen short of addressing the true underlying causes of these persistent conditions, leaving millions without effective treatment or hope.

Founded by Dr. William Pridgen, a distinguished physician, researcher, and surgeon with over 35 years of medical innovation and clinical experience, PridCor Therapeutics was established to challenge the status quo. Throughout his career, Dr. Pridgen has pursued new treatment approaches for complex illnesses largely overlooked by conventional markets, seeking practical answers to real barriers in healthcare delivery.

Leveraging this deep clinical insight and decades of dedicated research, PridCor Therapeutics is developing investigational combination regimens designed to address proposed biological drivers of post-viral syndromes. The same approach may prove relevant to other complex conditions including Fibromyalgia, ME/CFS, and IBS. Each application will require its own clinical evaluation.”

At PridCor Therapeutics, we are committed to generating the controlled clinical evidence this category has lacked, so that patients and physicians can eventually make decisions based on data rather than hope.”